BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 37473808)

  • 21. The CD47-SIRPα axis is a promising target for cancer immunotherapies.
    Hao Y; Zhou X; Li Y; Li B; Cheng L
    Int Immunopharmacol; 2023 Jul; 120():110255. PubMed ID: 37187126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
    Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
    J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bionic lipoprotein loaded with chloroquine-mediated blocking immune escape improves antitumor immunotherapy.
    Dong Q; Han D; Li B; Yang Y; Ren L; Xiao T; Zhang J; Li Z; Yang H; Liu H
    Int J Biol Macromol; 2023 Jun; 240():124342. PubMed ID: 37030459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular Magnetic Hyperthermia Enables Concurrent Down-Regulation of CD47 and SIRPα To Potentiate Antitumor Immunity.
    Wang S; Jiao W; Yan B; Liu X; Tang Q; Zhang Y; Liang C; Wang X; Lyu Y; Fan H; Liu X
    Nano Lett; 2024 Mar; 24(9):2894-2903. PubMed ID: 38407042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
    Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
    J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy.
    Zhao W; Hu X; Li W; Li R; Chen J; Zhou L; Qiang S; Wu W; Shi S; Dong C
    Small; 2021 Apr; 17(13):e2007051. PubMed ID: 33599061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
    Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
    Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
    Stefanidis E; Semilietof A; Pujol J; Seijo B; Scholten K; Zoete V; Michielin O; Sandaltzopoulos R; Coukos G; Irving M
    J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38828721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis.
    Chen XJ; Guo CH; Wang ZC; Yang Y; Pan YH; Liang JY; Sun MG; Fan LS; Liang L; Wang W
    Cell Commun Signal; 2024 Jan; 22(1):15. PubMed ID: 38183060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer.
    Chang R; Chu X; Zhang J; Fu R; Feng C; Jia D; Wang R; Yan H; Li G; Li J
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy.
    Cao A; Yi J; Tang X; Szeto CW; Wu R; Wan B; Fang X; Li S; Wang L; Wang L; Li J; Ye Q; Huang T; Hsu K; Kabbarah O; Zhou H
    Cancer Res Commun; 2022 Nov; 2(11):1404-1417. PubMed ID: 36970051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
    Anfray C; Mainini F; Digifico E; Maeda A; Sironi M; Erreni M; Anselmo A; Ummarino A; Gandoy S; Expósito F; Redrado M; Serrano D; Calvo A; Martens M; Bravo S; Mantovani A; Allavena P; Andón FT
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
    Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
    Hu Z; Li W; Chen S; Chen D; Xu R; Zheng D; Yang X; Li S; Zhou X; Niu X; Xiao Y; He Z; Li H; Liu J; Sui X; Gao Y
    Sci China Life Sci; 2023 Oct; 66(10):2310-2328. PubMed ID: 37115491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma.
    Xiao A; Akilov OE
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lactate-Responsive Gene Editing to Synergistically Enhance Macrophage-Mediated Cancer Immunotherapy.
    Li Y; Wei Y; Huang Y; Qin G; Zhao C; Ren J; Qu X
    Small; 2023 Aug; 19(35):e2301519. PubMed ID: 37156740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.
    Cheng L; Zhang X; Tang J; Lv Q; Liu J
    Biomaterials; 2021 Aug; 275():120964. PubMed ID: 34147721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.